ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2518

The Sphingosine-1-Phosphate Pathway Is a Key Regulator of Bone Substrate-Mediated Osteoclast Differentiation in Inflammatory Arthritis

P. Edward Purdue1, Jon Hill2, Steven R. Goldring3, Nikolaus, B. Binder3, Jennifer L. Swantek4, Zhenxin Shen5, Tania N. Crotti5, Gerald H. Nabozny4 and Kevin P. McHugh5, 1Research, Hospital for Special Surgery, New York, NY, 2Scientific Knowledge Discovery, Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, CT, 3Hospital for Special Surgery, New York, NY, 4Immunology and Inflammation, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, 5Orthopedic Surgery, Center for Advanced Orthopedic Studies, Beth Israel Deaconess Medical Center, Boston, MA

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Inflammation, osteoclastogenesis and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Biology and Pathology of Bone and Joint: Regulation of Bone Cells

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Multiple lines of evidence have established that osteoclasts are required for physiologic bone resorption and pathological bone loss in inflammatory disorders. Isolation of differentiated osteoclasts from bone is technically challenging, but with the discovery that M-CSF and RANKL are sufficient for osteoclast differentiation came the ability to generate multinucleated osteoclasts from myeloid precursor cells in vitro with high efficiency. In vivo, analysis of osteoclasts at sites of bone resorption reveals that functionally activated osteoclasts are almost exclusively localized to the immediate bone surface, indicating that cell-substrate interactions contribute to terminal osteoclast differentiation. In this study, we have employed a unique in vitro osteoclastogenesis system using authentic bone substrates and expression profiling and pathway analysis to identify critical bone substrate-mediated pathways of osteoclast formation and activation. We have further validated the sphingosine-1-phosphate (S1P) generation, transport and signaling pathway as a key component of the bone-substrate regulated osteoclast differentiation program in vitro and in vivo.

Methods:

Murine bone marrow derived macrophages were cultured in the presence or absence of RANKL on plastic, hydroxyapatite, or calvarial bone discs. RNA was isolated at different stages of osteoclast generation and subjected to microarray analysis. Pathway analysis was performed using GSEA and Ingenuity pathway analysis. SphK inhibitors were used to validate involvement of S1P signaling in osteoclastogenesis in vitro. Immunohistochemical analysis of the RA bone-pannus interface was used assess activation of this pathway in osteoclasts in vivo.

Results:

Microarray analysis revealed unique clusters of RANKL induced and bone substrate-modulated osteoclast genes. Of 1490 genes upregulated by RANKL in differentiated osteoclasts, 5.4% were further upregulated by culture on the bone substrate; an additional 8.5% were downregulated. Pathway analysis identified the S1P pathway as significantly regulated by both RANKL and bone substrate, and that this regulation was dependent upon the presence of integrin beta 3, a key mediator of osteoclast attachment to bone.  SphK inhibitors dose-dependently blocked RANKL-induced human and mouse osteoclastogenesis in vitro. Furthermore, SphK1 was highly induced in osteoclasts at sites of RA bone erosions.

Conclusion:

Interaction of osteoclasts with the bone surface regulates multiple critical pathways of osteoclast formation and activation. Pathway analysis and in vitro/in vivo validation identifies the S1P pathway as a critical regulator of RANKL-bone-dependent osteoclastogenesis.  This pathway represents a novel therapeutic target for preventing osteoclast-mediated bone destruction in inflammatory bone loss disorders.


Disclosure:

P. E. Purdue,

Boehringer Ingelheim,

2;

J. Hill,

Boehringer Ingelheim,

3;

S. R. Goldring,

Boehringer Ingelheim,

2;

N. B. Binder,

Boehringer Ingelheim,

2;

J. L. Swantek,

Boehringer Ingelheim,

3;

Z. Shen,

Boehringer Ingelheim,

2;

T. N. Crotti,

Boehringer Ingelheim,

2;

G. H. Nabozny,

Boehringer Ingelheim,

3;

K. P. McHugh,

Boehringer Ingelheim,

2.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-sphingosine-1-phosphate-pathway-is-a-key-regulator-of-bone-substrate-mediated-osteoclast-differentiation-in-inflammatory-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology